In June, the Food and Drug Administration approved the first vaccine developed to protect women against cervical cancer. Known as Gardasil and developed by Merck & Co., the drug is highly effective against four types of human papillomavirus, including two that cause cervical cancer.
In June, the Food and Drug Administration approved the first vaccine developed to protect women against cervical cancer. Known as Gardasil and developed by Merck & Co., the drug is highly effective against four types of human papillomavirus, including two that cause cervical cancer.
The Centers for Disease Control and Prevention's Advisory Committee on Immunization has recommended that the vaccination series be given routinely to girls aged 11 to 12. It also noted that the series can be given to girls as early as 9 years of age at the discretion of physicians, and to girls and women who are 13 to 26 years old. The vaccine should be administered before the onset of sexual activity (before women are exposed to the virus), but women who are sexually active may still be vaccinated.
Controversy surrounds the drug already, as the cost has raised concerns that lower-income women may not be able to afford the drug, according to The Washington Post (6/9/06)-the vaccine will cost $120 per dose and protection will require three doses over 6 months). Moreover, social conservatives, who advocate abstinence as the best way to avoid getting HPV, oppose the mandatory use of vaccination. In contrast, women's and public health groups support early and mandatory vaccinations. Such decisions, though, will be made on a state-by-state basis.
Unlocking HPV prevention: Insights from 2022 data on vaccination trends
May 14th 2024Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More
Understanding pediatric STIs: Trends, management, and more
May 10th 2024Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More